Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356421 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00356421 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 58 participants.
The verdict
NCT00356421, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
Interventions
- DRUG Inhaled Human Insulin (Exubera®)
- DRUG Insulin lispro (Humalog)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356421
The ClinicalTrials.gov registry entry for NCT00356421 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inhaled Human Insulin (Exubera®) is the first listed.
NCT00356421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356421 about?
NCT00356421 is a clinical study titled "A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®". To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
What is the current status of trial NCT00356421?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2006-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00356421?
The interventions under investigation include: Inhaled Human Insulin (Exubera®) (DRUG), Insulin lispro (Humalog) (DRUG).
Who is sponsoring clinical trial NCT00356421?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.